8HFV

Crystal structure of CTSL in complex with K777

8HFV の概要

• エントリーDOI: 10.2210/pdb8hfv/pdb
• 関連するBIRD辞書のPRD_ID: PRD_000325
• 分子名称: Procathepsin L, ZINC ION, CACODYLATE ION, ... (5 entities in total)
• 機能のキーワード: inhibitor, antiviral, protease, antiviral protein, hydrolase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 102001.16

構造登録者

Wang, H.,Shao, M.,Sun, L.,Yang, H. (登録日: 2022-11-12, 公開日: 2023-12-13, 最終更新日: 2024-10-30)

主引用文献

Wang, H.,Yang, Q.,Liu, X.,Xu, Z.,Shao, M.,Li, D.,Duan, Y.,Tang, J.,Yu, X.,Zhang, Y.,Hao, A.,Wang, Y.,Chen, J.,Zhu, C.,Guddat, L.,Chen, H.,Zhang, L.,Chen, X.,Jiang, B.,Sun, L.,Rao, Z.,Yang, H.
Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry.
Nat Commun, 14:7574-7574, 2023

PubMed Abstract: Since 2019, SARS-CoV-2 has evolved rapidly and gained resistance to multiple therapeutics targeting the virus. Development of host-directed antivirals offers broad-spectrum intervention against different variants of concern. Host proteases, TMPRSS2 and CTSL/CTSB cleave the SARS-CoV-2 spike to play a crucial role in the two alternative pathways of viral entry and are characterized as promising pharmacological targets. Here, we identify compounds that show potent inhibition of these proteases and determine their complex structures with their respective targets. Furthermore, we show that applying inhibitors simultaneously that block both entry pathways has a synergistic antiviral effect. Notably, we devise a bispecific compound, 212-148, exhibiting the dual-inhibition ability of both TMPRSS2 and CTSL/CTSB, and demonstrate antiviral activity against various SARS-CoV-2 variants with different viral entry profiles. Our findings offer an alternative approach for the discovery of SARS-CoV-2 antivirals, as well as application for broad-spectrum treatment of viral pathogenic infections with similar entry pathways.

PubMed: 37990007
DOI: 10.1038/s41467-023-42527-5

実験手法

X-RAY DIFFRACTION (2.1 Å)